Optiscan Imaging Launches First Clinical Device into US Veterinary Market

Optiscan Imaging (ASX: OIL) has launched its InSpecta microscopic imaging device into the US veterinary market after successfully submitting its regulatory dossier to the United States Food and Drug Administration (FDA) Centre for Veterinary Medicine.

The launch gives Optiscan its first commercial clinical device in the US market and marks a key step in its transition from technology and product developer to commercial-stage medical technology business.

InSpecta delivers real-time cellular imaging at the point of care, giving veterinary practices a new in-house capability designed to support faster clinical insight, improved workflow efficiency and potential new revenue streams.

Optiscan will showcase the device to veterinarians, specialists and practice decision-makers at the American Veterinary Medical Association (AVMA) Convention 2026 in Anaheim, California from 10 to 14 July.

US Market Entry

The FDA Centre for Veterinary Medicine submission enables Optiscan to commence commercial sales activity for InSpecta in the US veterinary healthcare market.

Optiscan views the submission as a critical value inflection point because it removed the principal regulatory hurdle to US commercialisation of the device.

The milestone also validates the company’s ability to navigate regulatory requirements for broader US healthcare market access.

By entering veterinary medicine, Optiscan is extending its proprietary imaging technology beyond human healthcare into a large sector with growing demand for advanced diagnostics and faster clinical decision-making.

Imaging Platform Broadens

InSpecta has been purpose-designed for specialist hospitals, general practices, mobile services, and field-based veterinary care.

The device aims to bridge the gap between clinical examination and laboratory-based diagnostics by bringing microscopic imaging into the veterinary workflow, and has potential applications across specialist hospitals, general practices, mobile services, and field-based care.

The FDA CVM submission is seen as a critical value inflection point because it removes the principal regulatory hurdle to US commercialisation of InSpecta, while also giving Optiscan internal experience and a validated pathway that could support future US submissions across its broader product pipeline.

Commercial deployment in the veterinary market creates a US beachhead for the company’s imaging technology while extending the platform beyond human healthcare.

Optiscan believes this diversification demonstrates the adaptability of its technology across multiple healthcare markets and strengthens its position as it advances other devices through human patient studies.

Large Veterinary Market

A Grand View Research-prepared report valued the US veterinary services market at approximately US$15.87 billion in 2024 and projected that to grow to more than US$30b by 2033, with American Pet Products Association data showing 71% of US households own a pet.

Rising demand for advanced veterinary care—including the management of complex conditions such as cancer—is creating a need for technologies that can improve clinical insight and reduce diagnostic delays.

Chief executive officer Dr Camile Farah described the launch as a defining development milestone for Optiscan.

“The US launch of InSpecta validates the maturity of our imaging platform and establishes a repeatable regulatory and commercial pathway for other already revealed products that utilise our proprietary imaging technology,” Dr Farah said.

"It represents one important step in Optiscan’s transition into a commercial-stage medical technology company—and more such steps are expected to follow as we continue to progress multiple human patient studies involving our other devices.”